Table of Contents

company-logo

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GT Biopharma Dividend Announcement

• GT Biopharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on GT Biopharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

GT Biopharma Dividend History

GT Biopharma Dividend Yield

GT Biopharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing GT Biopharma stock? Use our calculator to estimate your expected dividend yield:

GT Biopharma Financial Ratios

P/E ratio-0.52
PEG ratio0.00
P/B ratio1.08
ROE-160.47%
Payout ratio0.00%
Current ratio2.47
Quick ratio2.47
Cash Ratio0.71

GT Biopharma Dividend FAQ

Does GT Biopharma stock pay dividends?
GT Biopharma does not currently pay dividends to its shareholders.
Has GT Biopharma ever paid a dividend?
No, GT Biopharma has no a history of paying dividends to its shareholders. GT Biopharma is not known for its dividend payments.
Why doesn't GT Biopharma pay dividends?
There are several potential reasons why GT Biopharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will GT Biopharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While GT Biopharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is GT Biopharma a dividend aristocrat?
GT Biopharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is GT Biopharma a dividend king?
GT Biopharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is GT Biopharma a dividend stock?
No, GT Biopharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy GT Biopharma stocks?
To buy GT Biopharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy GT Biopharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.